JACC: Advances (Aug 2024)

Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis

  • Nerea Mora-Ayestaran, MD,
  • Angela Dispenzieri, MD,
  • Arnt V. Kristen, MD,
  • Mathew S. Maurer, MD,
  • Igor Diemberger, MD,
  • Brian M. Drachman, MD,
  • Martha Grogan, MD,
  • Pritam Gupta, PhD,
  • Oliver Glass, PhD,
  • Leslie Amass, PhD,
  • Pablo Garcia-Pavia, MD, PhD,
  • Michele Emdin,
  • Mazen Hanna,
  • Olga Azevedo,
  • Calogero Lino Cirami,
  • Jose Gonzalez Costello,
  • David Slosky,
  • Henning Moelgaard,
  • Jose Nativi Nicolau,
  • Scott Hummel,
  • Eun-Seok Jeon,
  • Nowell Fine,
  • Srinivas Murali,
  • Edward Miller,
  • Sanjiv Shah,
  • Ronald Witteles,
  • Marcia Waddington-Cruz,
  • Daniel Lenihan,
  • Yoshiki Sekijima,
  • Johan Van Cleemput,
  • Edileide de Barros Correia,
  • Eve Cariou,
  • Dianna Quan,
  • Miriam Freimer,
  • David Steidley,
  • Anna Hüsing-Kabar,
  • Violaine Plante-Bordeneuve,
  • Hans Nienhuis,
  • Jonas Wixner,
  • Jeffrey Ralph,
  • Hector Ventura,
  • Sasa Zivkovic,
  • Diego Delgado,
  • Roberto Fernandéz Torrón,
  • Stephen Gottlieb,
  • William Cotts,
  • Jose Tallaj,
  • Robert Brunkhorst,
  • Michael Polydefkis,
  • Christopher Mueller,
  • Carsten Tschoepe,
  • Juan Gonzalez Moreno,
  • Nitasha Sarswat,
  • Jin Luo,
  • James Tauras,
  • Alberta Warner

Journal volume & issue
Vol. 3, no. 8
p. 101086

Abstract

Read online

Background: Wild-type transthyretin amyloidosis (ATTRwt amyloidosis) is primarily diagnosed in elderly men but diagnoses in younger patients and women have recently increased. Objectives: The purpose of this study was to examine age- and sex-related differences in patients with ATTRwt amyloidosis enrolled in the THAOS (Transthyretin Amyloidosis Outcomes Survey). Methods: THAOS was a global, longitudinal, observational survey of patients with transthyretin amyloidosis, including both hereditary and wild-type disease, and asymptomatic carriers of pathogenic transthyretin gene variants. Patient characteristics at enrollment were analyzed by age at enrollment and sex (data cutoff date: August 1, 2022). Results: Of 1,251 patients with ATTRwt amyloidosis, 13.7%, 49.1%, 34.5%, and 2.8% were aged <70 years, 70 to 79 years, 80 to 89 years, and ≥90 years, respectively. The proportion of women increased with age, from 4.1% in patients aged <70 years to 14.3% in patients aged ≥90 years. In the respective age groups, median time from symptom onset to diagnosis overall (male, female) was 1.7 (1.3, 5.2), 2.0 (2.0, 2.2), 1.8 (1.9, 0.8), and 0.7 (0.6, 2.5) years. A Karnofsky Performance Status score ≤70 was observed in 17.1%, 30.1%, 46.1%, and 44.4% of patients aged <70 years, 70 to 79 years, 80 to 89 years, and ≥90 years, respectively. Conclusions: In this THAOS analysis of patients with ATTRwt amyloidosis, patients were diagnosed an average of 2 years after symptom onset, with the greatest diagnostic delay in women aged <70 years at 5 years. Patients were predominantly men, but the proportion of women increased with age. A substantial proportion of patients had significant functional impairment regardless of age. (Transthyretin Amyloidosis Outcome Survey [THAOS]; NCT00628745)

Keywords